Compare NYAX & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | TLX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2022 | N/A |
| Metric | NYAX | TLX |
|---|---|---|
| Price | $59.40 | $10.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $49.50 | $21.13 |
| AVG Volume (30 Days) | 11.1K | ★ 192.3K |
| Earning Date | 05-12-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $21.70 | N/A |
| P/E Ratio | ★ $89.78 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.18 | $6.28 |
| 52 Week High | $61.66 | $19.93 |
| Indicator | NYAX | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 74.32 |
| Support Level | $42.69 | $9.46 |
| Resistance Level | $61.21 | $11.18 |
| Average True Range (ATR) | 1.28 | 0.30 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 78.29 | 90.44 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.